Excel, with all due respect, I think you're being unrealistically optimistic. To say ADXS could be bought in a year to a year and a half for $5 billion would equate to nearly a 2,000% return from the current valuation. ADXS has a market cap of under $300 million and that includes the market knowledge that ADXS is submitting for conditional Europe approval. I think you're overestimated the size of the European market for a cervical cancer treatment. Don't get me wrong, it will be a great step forward for the company to get approval in any market and pave the way for more approvals, but I think it's unrealistic to think the stock will appreciate and lead to a buyout shortly thereafter at 20x the current price. If we can get back to the analysts consensus fair value of $23 a share this year, I think we should all be very happy. Then if a buyout eventually happens for $50/$2 billion valuation, that would be great IMO. The days of DO forecasting a $50 stock price by 2015 and $6 billion end valuation are over IMO and were simply part of his original inflated thinking to justify his huge pre-paid bonus awards to himself.
News 
Market Data 
Discover 
